来源|贝多财经 5月9日晚间，迈威（上海）生物科技股份有限公司（下称"迈威生物"，SH:688062）发布公告，称收到该公司董事长兼总经理刘大涛通知，其于近日收到中 国证监会出具的《立案告知书》。 因涉嫌短线交易，中国证监会根据规定，决定对刘大涛立案。迈威生物在公告表示，本次事项系对刘大涛个人的调查，不会对该公司日常经营活动产生重大 影响，立案调查期间，刘大涛将积极配合中国证监会开展调查工作。 据贝多财经了解，迈威生物是一家科创板上市公司，于2022年1月18日在上海证券交易所科创板上市，IPO发行价为34.8元/股，发行数量为9990万股，募资 总额约34.77亿元，募资净额，募资净额约33亿元。 | 序号 | 项目名称 | 投资总额 | 拟投入募集资 | | --- | --- | --- | --- | | | 年产1,000kg抗体产业化建设项目 | 160,151.70 | 120 | | 2 | 抗体药物研发项目 | 100,000.00 | 100 | | 3 | 补充流动资金 | 78,000.00 | 78 | | | 合计 | 338,151.70 | 298 | 上市首日，迈威生物就跌破 ...

Core Viewpoint - The chairman and general manager of Maiwei Biotech, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which may impact the company's operations and market confidence [1][2][10]. Company Overview - Maiwei Biotech was founded in May 2017 and went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2022, focusing on innovative biopharmaceuticals across various therapeutic areas [6]. - The company has experienced significant revenue growth but has faced substantial net losses since its listing [7]. Financial Performance - In 2022, Maiwei Biotech reported revenue of 27.73 million yuan, a year-on-year increase of 70.88%, but incurred a net loss of 955 million yuan [7]. - Revenue rose to 128 million yuan in 2023, a 361.03% increase, yet the net loss expanded to 1.053 billion yuan [7]. - For 2024, revenue further increased to 200 million yuan, a 56.28% growth, but the net loss remained high at 1.044 billion yuan [7]. Cost and Investment - The company attributes revenue growth to successful market expansion and increased sales of its core products, but rising operating costs and high R&D expenses have compressed profit margins [8]. - R&D expenses were reported at 759 million yuan in 2022, 836 million yuan in 2023, and 783 million yuan in 2024, indicating sustained high investment levels [8]. Market Sentiment - Maiwei Biotech's stock price has been declining, with a cumulative drop of over 12% from April 25 to May 9 [5]. - The ongoing investigation into the chairman may further dampen market confidence and complicate the company's plans for an H-share listing in Hong Kong [10].

作 者丨闫硕 编 辑丨季媛媛 5 月 9 日 晚 间 ， 迈 威 生 物 （ 6 8 8 0 6 2 .SH ） 发 布 公 告 ， 收 到 公 司 董 事 长 兼 总 经 理 刘 大 涛 先 生 通 知，其于近日收到中国证监会出具的《立案告知书》。因涉嫌短线交易，中国证监会根据相关 法律法规，决定对其立案。 迈威生物表示，本次事项系对刘大涛先生个人的调查，不会对公司日常经营活动产生重大影 响。公司将持续关注进展情况并履行信息披露义务。 公开资料显示，迈威生物是一家全产业链布局的创新型生物制药公司，主营业务为研发、生产 以及销售创新型药物和生物类似药，主要产品为抗体、ADC 药物和重组蛋白、小分子化学药 等药物。目前已有三款产品上市销售，产品逐步放量。但也需要指出， 迈威生物自2 0 1 7年成 立至今并未盈利，累计亏损近6 0亿元 。 董事长被立案 根据迈威生物2 0 2 4年年报，刘大涛现年5 2岁，为公司法定代表人，目前持股1 5 1 0万股，持股 比例为3 . 7 8%，2 0 2 4年从公司获得的税前报酬总额为2 7 0 . 4 7万元。 刘大涛与生物医药结缘多年，其在1 9 8 9年考入吉林大学分 ...

21世纪经济报道记者 闫硕 北京报道 5月9日晚间，迈威生物（688062.SH）发布公告，收到公司董事长兼总经理刘大涛先生通知，其于近日 收到中国证监会出具的《立案告知书》。因涉嫌短线交易，中国证监会根据相关法律法规，决定对其立 案。 根据迈威生物2024年年报，刘大涛现年52岁，为公司法定代表人，目前持股1510万股，持股比例为 3.78%，2024年从公司获得的税前报酬总额为270.47万元。 刘大涛与生物医药结缘多年，其在1989年考入吉林大学分子生物学系，分别于1993年、1996年在该校获 得学士学位和硕士学位，2000年7月又获得沈阳药科大学药物化学博士学位。 毕业后，刘大涛进入上海莱士血制品有限公司任研究员，2000年10月又进入上海医药集团工作，2011年 1月至2017年6月任上海医药集团股份有限公司中央研究院副院长、研发总监、生物药物研究室主任。 2017年，刘大涛与唐春山联合创立迈威生物，由此踏上创新药的创业之路。2020年6月至今，刘大涛任 公司董事、总经理；2023年6月至今，其任公司董事长。 年报显示，目前迈威生物的实际控制人为唐春山、陈姗娜夫妇，对公司表决权比例为42.38%。 ...

Core Viewpoint - Maiwei Biopharma is advancing multiple key pipeline products in critical registration clinical research stages, with its core pipeline 9MW2821 being the first of its kind globally to enter Phase III for cervical cancer [2][3] Group 1: Pipeline and Clinical Trials - The company has 16 pipeline products in various stages, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [2] - 9MW2821 is involved in multiple indications, including urothelial carcinoma (UC), cervical cancer (CC), triple-negative breast cancer (TNBC), and esophageal cancer (EC), with over 800 patients enrolled in clinical trials [3] - Three Phase III clinical trials are ongoing for 9MW2821, making it the first domestic product for UC and the second globally [3] Group 2: ADC Development Platform - Maiwei Biopharma is enhancing its proprietary ADC drug development platform to improve the efficacy and safety of ADC molecules [3] - The company’s ADC platform utilizes site-specific conjugation technology, resulting in higher uniformity and reduced batch-to-batch variability compared to traditional methods [3] Group 3: Commercial Performance - In 2024, the company achieved revenue of 200 million yuan, a year-on-year increase of 56.28%, with sales of its drug for bone diseases and tumors reaching 139 million yuan, a 230% increase [5] - The company has three marketed products and is expecting to launch another innovative drug in December 2023, with potential approval in 2025 [5] Group 4: Strategic Collaborations - Maiwei Biopharma signed a contract for a bone health innovation drug project with the Chongqing High-tech Industrial Development Zone, aiming to promote its products in local medical institutions [5] - The project is expected to cover over 1 million elderly individuals annually through new service models [5]